Frontiers in Immunology (Feb 2012)

Targeting dendritic cells in vivo for cancer therapy

  • Irina eCaminschi,
  • Irina eCaminschi,
  • Eugene eMaraskovsky,
  • William Ross Heath

DOI
https://doi.org/10.3389/fimmu.2012.00013
Journal volume & issue
Vol. 3

Abstract

Read online

Monoclonal antibodies that recognise cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumour immunity elicited using this immunisation strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialisation of DC-subsets, the immunological outcomes of targeting different DC-subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumour immunity. Finally, we review preclinical experiments and the progress towards targeting human DC in vivo.

Keywords